ParkinsonCanadaV1, Main, Exploration, bibRecord, 002914

Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys

Identifieur interne : 002914 ( Main/Exploration ); précédent : 002913; suivant : 002915

Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys

Auteurs : Carl Julien [Canada] ; Line Berthiaume [Canada] ; Abdallah Hadj-Tahar [Canada] ; Ali H. Rajput [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Pierre Julien [Canada] ; Frédéric Calon [Canada]

Source :

Neurochemistry international [ 0197-0186 ] ; 2006.

RBID : Pascal:06-0205655

Descripteurs français

Pascal (Inist)
- Postmortem, Acide gras, Lévodopa, Matière grasse, Acide gras polyinsaturé, Acide gras saturé, Neurotoxine, Parkinson maladie, Homme, Singe, MPTP.
Wicri :
- topic : Homme, Singe.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Animals, Arachidonic Acid (metabolism), Cerebral Cortex (drug effects), Cerebral Cortex (metabolism), Cerebral Cortex (physiopathology), Chromatography, Gas, Dietary Fats (metabolism), Disease Models, Animal, Docosahexaenoic Acids (metabolism), Dopamine Agents (pharmacology), Dyskinesia, Drug-Induced (metabolism), Dyskinesia, Drug-Induced (physiopathology), Fat, Fatty Acids (metabolism), Fatty Acids, Unsaturated (metabolism), Fatty acids, Female, Human, Humans, Levodopa, Levodopa (pharmacology), Lipid Metabolism (drug effects), Lipid Metabolism (physiology), Macaca fascicularis, Male, Monkey, Neurons (drug effects), Neurons (metabolism), Neurotoxin, Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Parkinson disease, Parkinsonian Disorders (metabolism), Parkinsonian Disorders (physiopathology), Polyunsaturated fatty acid, Postmortem, Postmortem Changes, Saturated fatty acid, Species Specificity.
MESH :
- chemical , metabolism : Arachidonic Acid, Dietary Fats, Docosahexaenoic Acids, Fatty Acids, Fatty Acids, Unsaturated.
- drug effects : Cerebral Cortex, Lipid Metabolism, Neurons.
- metabolism : Cerebral Cortex, Dyskinesia, Drug-Induced, Neurons, Parkinson Disease, Parkinsonian Disorders.
- chemical , pharmacology : Dopamine Agents, Levodopa.
- physiology : Lipid Metabolism.
- physiopathology : Cerebral Cortex, Dyskinesia, Drug-Induced, Parkinson Disease, Parkinsonian Disorders.
- Aged, Aged, 80 and over, Animals, Chromatography, Gas, Disease Models, Animal, Female, Humans, Macaca fascicularis, Male, Postmortem Changes, Species Specificity.

Abstract

Fatty acids play a critical role in brain function but their specific role in the pathophysiology of Parkinson disease (PD) and levodopa-induced motor complications is still unknown. From a therapeutic standpoint, it is important to determine the relation between brain fatty acids and PD because the brain fatty acid content depends on nutritional intake, a readily manipulable environmental factor. Here, we report a postmortem analysis of fatty acid profile by gas chromatography in the brain cortex of human patients (12 PD patients and nine Controls) as well as in the brain cortex of monkeys (four controls, five drug-naive MPTP monkeys and seven levodopa-treated MPTP monkeys). Brain fatty acid profile of cerebral cortex tissue was similar between PD patients and Controls and was not correlated with age of death, delay to autopsy or brain pH. Levodopa administration in MPTP monkeys increased arachidonic acid content (+7%; P < 0.05) but decreased docosahexaenoic acid concentration (-15%; P < 0.05) and total n - 3:n - 6 polyunsaturated fatty acids ratio (-27%; P < 0.01) compared to drug-naive MPTP animals. Interestingly, PD patients who experienced motor complications to levodopa had higher arachidonic acid concentrations in the cortex compared to Controls (+13.6%; P < 0.05) and to levodopa-treated PD patients devoid of motor complications (+14.4%; P < 0.05). Furthermore, PD patients who took an above-median cumulative dose of levodopa had a higher relative amount of saturated fatty acids but lower monounsaturated fatty acids in their brain cortex (P < 0.01). These results suggest that changes in brain fatty acid relative concentrations are associated with levodopa treatment in PD patients and in a non-human primate model of parkinsonism.

Affiliations:

Canada

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys</title>
<author><name sortKey="Julien, Carl" sort="Julien, Carl" uniqKey="Julien C" first="Carl" last="Julien">Carl Julien</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Centre Hospitalier de l'Université Laval Research Centre (CHUL). 2705 Laurier Blvd</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Berthiaume, Line" sort="Berthiaume, Line" uniqKey="Berthiaume L" first="Line" last="Berthiaume">Line Berthiaume</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Quebec Lipid Research Centre, CHUL</s1>
<s2>Que., C1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., C1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hadj Tahar, Abdallah" sort="Hadj Tahar, Abdallah" uniqKey="Hadj Tahar A" first="Abdallah" last="Hadj-Tahar">Abdallah Hadj-Tahar</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Research Unit, CHUL</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Neurology. University of Saskatchewan, Royal University Hospital</s1>
<s2>Sask</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Sask</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Research Unit, CHUL</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Centre Hospitalier de l'Université Laval Research Centre (CHUL). 2705 Laurier Blvd</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Julien, Pierre" sort="Julien, Pierre" uniqKey="Julien P" first="Pierre" last="Julien">Pierre Julien</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Quebec Lipid Research Centre, CHUL</s1>
<s2>Que., C1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., C1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Centre Hospitalier de l'Université Laval Research Centre (CHUL). 2705 Laurier Blvd</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0205655</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0205655 INIST</idno>
<idno type="RBID">Pascal:06-0205655</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000847</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000476</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000708</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000708</idno>
<idno type="wicri:doubleKey">0197-0186:2006:Julien C:postmortem:brain:fatty</idno>
<idno type="wicri:Area/Main/Merge">002C06</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16442670</idno>
<idno type="wicri:Area/PubMed/Corpus">001181</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001181</idno>
<idno type="wicri:Area/PubMed/Curation">001181</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001181</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001181</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001181</idno>
<idno type="wicri:Area/Ncbi/Merge">000610</idno>
<idno type="wicri:Area/Ncbi/Curation">000610</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000610</idno>
<idno type="wicri:doubleKey">0197-0186:2006:Julien C:postmortem:brain:fatty</idno>
<idno type="wicri:Area/Main/Merge">002999</idno>
<idno type="wicri:Area/Main/Curation">002914</idno>
<idno type="wicri:Area/Main/Exploration">002914</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys</title>
<author><name sortKey="Julien, Carl" sort="Julien, Carl" uniqKey="Julien C" first="Carl" last="Julien">Carl Julien</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Centre Hospitalier de l'Université Laval Research Centre (CHUL). 2705 Laurier Blvd</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Berthiaume, Line" sort="Berthiaume, Line" uniqKey="Berthiaume L" first="Line" last="Berthiaume">Line Berthiaume</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Quebec Lipid Research Centre, CHUL</s1>
<s2>Que., C1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., C1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hadj Tahar, Abdallah" sort="Hadj Tahar, Abdallah" uniqKey="Hadj Tahar A" first="Abdallah" last="Hadj-Tahar">Abdallah Hadj-Tahar</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Research Unit, CHUL</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Neurology. University of Saskatchewan, Royal University Hospital</s1>
<s2>Sask</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Sask</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Research Unit, CHUL</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Centre Hospitalier de l'Université Laval Research Centre (CHUL). 2705 Laurier Blvd</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Julien, Pierre" sort="Julien, Pierre" uniqKey="Julien P" first="Pierre" last="Julien">Pierre Julien</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Quebec Lipid Research Centre, CHUL</s1>
<s2>Que., C1V 4G2</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., C1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Centre Hospitalier de l'Université Laval Research Centre (CHUL). 2705 Laurier Blvd</s1>
<s2>Que., G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Que., G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Que., G1K 7P4</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurochemistry international</title>
<title level="j" type="abbreviated">Neurochem. int.</title>
<idno type="ISSN">0197-0186</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurochemistry international</title>
<title level="j" type="abbreviated">Neurochem. int.</title>
<idno type="ISSN">0197-0186</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Arachidonic Acid (metabolism)</term>
<term>Cerebral Cortex (drug effects)</term>
<term>Cerebral Cortex (metabolism)</term>
<term>Cerebral Cortex (physiopathology)</term>
<term>Chromatography, Gas</term>
<term>Dietary Fats (metabolism)</term>
<term>Disease Models, Animal</term>
<term>Docosahexaenoic Acids (metabolism)</term>
<term>Dopamine Agents (pharmacology)</term>
<term>Dyskinesia, Drug-Induced (metabolism)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Fat</term>
<term>Fatty Acids (metabolism)</term>
<term>Fatty Acids, Unsaturated (metabolism)</term>
<term>Fatty acids</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (pharmacology)</term>
<term>Lipid Metabolism (drug effects)</term>
<term>Lipid Metabolism (physiology)</term>
<term>Macaca fascicularis</term>
<term>Male</term>
<term>Monkey</term>
<term>Neurons (drug effects)</term>
<term>Neurons (metabolism)</term>
<term>Neurotoxin</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinsonian Disorders (metabolism)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Polyunsaturated fatty acid</term>
<term>Postmortem</term>
<term>Postmortem Changes</term>
<term>Saturated fatty acid</term>
<term>Species Specificity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Arachidonic Acid</term>
<term>Dietary Fats</term>
<term>Docosahexaenoic Acids</term>
<term>Fatty Acids</term>
<term>Fatty Acids, Unsaturated</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cerebral Cortex</term>
<term>Lipid Metabolism</term>
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cerebral Cortex</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Neurons</term>
<term>Parkinson Disease</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Lipid Metabolism</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cerebral Cortex</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Chromatography, Gas</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Humans</term>
<term>Macaca fascicularis</term>
<term>Male</term>
<term>Postmortem Changes</term>
<term>Species Specificity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Postmortem</term>
<term>Acide gras</term>
<term>Lévodopa</term>
<term>Matière grasse</term>
<term>Acide gras polyinsaturé</term>
<term>Acide gras saturé</term>
<term>Neurotoxine</term>
<term>Parkinson maladie</term>
<term>Homme</term>
<term>Singe</term>
<term>MPTP</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Fatty acids play a critical role in brain function but their specific role in the pathophysiology of Parkinson disease (PD) and levodopa-induced motor complications is still unknown. From a therapeutic standpoint, it is important to determine the relation between brain fatty acids and PD because the brain fatty acid content depends on nutritional intake, a readily manipulable environmental factor. Here, we report a postmortem analysis of fatty acid profile by gas chromatography in the brain cortex of human patients (12 PD patients and nine Controls) as well as in the brain cortex of monkeys (four controls, five drug-naive MPTP monkeys and seven levodopa-treated MPTP monkeys). Brain fatty acid profile of cerebral cortex tissue was similar between PD patients and Controls and was not correlated with age of death, delay to autopsy or brain pH. Levodopa administration in MPTP monkeys increased arachidonic acid content (+7%; P < 0.05) but decreased docosahexaenoic acid concentration (-15%; P < 0.05) and total n - 3:n - 6 polyunsaturated fatty acids ratio (-27%; P < 0.01) compared to drug-naive MPTP animals. Interestingly, PD patients who experienced motor complications to levodopa had higher arachidonic acid concentrations in the cortex compared to Controls (+13.6%; P < 0.05) and to levodopa-treated PD patients devoid of motor complications (+14.4%; P < 0.05). Furthermore, PD patients who took an above-median cumulative dose of levodopa had a higher relative amount of saturated fatty acids but lower monounsaturated fatty acids in their brain cortex (P < 0.01). These results suggest that changes in brain fatty acid relative concentrations are associated with levodopa treatment in PD patients and in a non-human primate model of parkinsonism.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Julien, Carl" sort="Julien, Carl" uniqKey="Julien C" first="Carl" last="Julien">Carl Julien</name>
</noRegion>
<name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<name sortKey="Berthiaume, Line" sort="Berthiaume, Line" uniqKey="Berthiaume L" first="Line" last="Berthiaume">Line Berthiaume</name>
<name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<name sortKey="Hadj Tahar, Abdallah" sort="Hadj Tahar, Abdallah" uniqKey="Hadj Tahar A" first="Abdallah" last="Hadj-Tahar">Abdallah Hadj-Tahar</name>
<name sortKey="Hadj Tahar, Abdallah" sort="Hadj Tahar, Abdallah" uniqKey="Hadj Tahar A" first="Abdallah" last="Hadj-Tahar">Abdallah Hadj-Tahar</name>
<name sortKey="Julien, Carl" sort="Julien, Carl" uniqKey="Julien C" first="Carl" last="Julien">Carl Julien</name>
<name sortKey="Julien, Pierre" sort="Julien, Pierre" uniqKey="Julien P" first="Pierre" last="Julien">Pierre Julien</name>
<name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002914 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002914 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:06-0205655
   |texte=   Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys

Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.